

# Expert Review of Neurotherapeutics

## **EDITORIAL**

**Neuregulin-1 signaling in schizophrenia**

## **DRUG PROFILES**

**Use of long-acting risperidone in psychiatric disorders**

**Lacosamide: pharmacology, mechanisms of action, efficacy and safety data**

## **MEETING REPORT**

**2008 annual meeting of the ISPN: highlights of the oncology session**

## **PERSPECTIVE**

**Treatment of schizophrenia in the 21st Century**

## **REVIEWS**

**Adjunctive lithium and anticonvulsants for the treatment of schizophrenia**

**Role of the cholinergic system in schizophrenia**

**GABAergic promoter hypermethylation as a model of schizophrenia**

**Obsessive-compulsive symptoms in schizophrenia**

**Assessment and treatment of suicide risk in bipolar disorders**

**Fracture risks of antidepressants**

01/05/21  
Expert Reviews Ltd  
1473-7175

**EXPERT  
REVIEWS**

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204

## Expert Review of

## Neurotherapeutics

January 2009

*Expert Rev. Neurother.* 9(1)**Editorial**

- 1 Neuregulin-1 signaling in schizophrenia: 'Jack of all trades' or master of some?  
CMP O'Tuathaigh, L Desbonnet & JL Waddington

5 **News in brief**

- Research urgently needed into off-label drug use
- Blood test for brain cancer
- Regulation of mitochondrial cell death in PD
- CGRP antagonist for migraine treatment
- Electric fields for chemotherapy of brain tumors
- Phase II trial of Atengenal and Astugenal

**Drug Profiles**

- 9 Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness  
S Keith
- 33 Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures  
A Beydoun, J D'Souza, D Hebert & P Doty

**Meeting Report**

- 43 The 2008 annual meeting of the International Society for Pediatric Neurosurgery (ISPN): highlights of the oncology session  
E Bouffet

**Perspective**

- 47 Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis  
DP Rogers & C-AW Goldsmith

**Reviews****SCHIZOPHRENIA**

- 55 Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?  
L Citrome
- 73 Role of the cholinergic system in the pathology and treatment of schizophrenia  
E Scarr & B Dean
- 87 GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability  
E Costa, Y Chen, E Dong, DR Grayson, M Kundakovic, E Maloku, W Ruzicka, R Satta, M Veldic, A Zhubi & A Guidotti
- 99 Obsessive-compulsive symptoms in schizophrenia: prevalence, correlates and treatment  
PH Lysaker & KA Whitney

**Mood**

- 109 Assessment and treatment of suicide risk in bipolar disorders  
M Pompili, Z Rihmer, M Innamorati, D Lester, P Girardi & R Tatarelli
- 137 Fracture risks of antidepressants  
P Vestergaard

**Appendices**

- 142 Glossary
- 143 Indices
- 145 Acknowledgements
- 146 Author Guidelines  
Calendar

EXPERT
REVIEWS

Managing Director  
James Drake  
Publisher  
David Hughes  
Editorial Director  
Elisa Manzotti

COMMISSIONING  
DEPARTMENT  
Head of Commissioning  
Laura Dormer  
Managing Commissioning  
Editor  
Sara Guy  
Commissioning Editor  
Lucy Tipton  
Assistant Commissioning  
Editor  
Genna Mann  
Drug Profiles Editor  
Linne Jenkin  
Assistant Drug Profiles  
Editor  
Sean Fitzpatrick

PRODUCTION DEPARTMENT  
Head of Production  
Karen Rowland  
Managing  
Production Editor  
Adam Williams  
Production Editor  
Philip Chapman  
Assistant  
Production Editors  
Francesca Watson  
Elizabeth Fox  
Katherine Gourd  
Siobhán Palmer  
Eleanor Maddox

ENQUIRIES

**Editorial** Elisa Manzotti, Editorial Director  
e.manzotti@expert-reviews.com  
**Subscription  
& Marketing** Simon Boisseau, Sales and Marketing Manager  
s.boisseau@expert-reviews.com  
**Reprint** Joanne Walker, Reprint Sales Manager  
j.walker@expert-reviews.com  
**Permissions** Leela Ripton, Permissions Coordinator  
l.ripton@expert-reviews.com  
**Online** Online Access Team  
subscriptions@expert-reviews.com

# Expert Review of Neurotherapeutics

## Editorial Board

The Editorial Board is drawn from the leading forces in research and academia

**Aminoff MJ**, UCSF, CA, USA  
**Benbadis SR**, University of South Florida, FL, USA  
**Billir J**, Loyola University Chicago, IL, USA  
**Brodie MJ**, University of Glasgow, Scotland, UK  
**Chamberlain MC**, Uni. of South Florida, Tampa, USA  
**Chesselet M-F**, UCLA, CA, USA  
**Diener H-C**, University of Essen, Germany  
**Donnan GA**, National Stroke Res. Inst., Australia  
**Drachman DA**, Uni. of MA Med. School, MA, USA  
**Gauthier FE**, Colorado State University, CP, USA  
**Gauthier S**, McGill Ctr for Studies in Aging, Canada  
**Giacobini E**, Uni. Hospitals of Geneva, Switzerland  
**Hardiman O**, Beaumont Hospital, Ireland  
**Hindmarch I**, HPRU Medical Research Centre, UK  
**Jankovic J**, Baylor College of Medicine, TX, USA  
**Jiménez-Jiménez FJ**, University of Alcalá, Spain  
**Kozubski W**, University of Medical Sciences, Poland  
**Krymchantowski AV**, Headache Ctr Rio de Janeiro  
**Lesniak MS**, University of Chicago, IL, USA  
**Lukasiewicz M**, INSERM, Paris, France  
**Lutsep HL**, Oregon Stroke Center, OR, USA  
**Mahapatra AK**, India Institute, New Delhi, India  
**Mastaglia FL**, Uni. of Western Australia, Australia  
**Nobile-Orazio E**, Milan University, Italy  
**Olanow W**, Mt. Sinai School of Medicine, NY, USA  
**Perry G**, University of Texas at San Antonio, USA  
**Perucca E**, University of Pavia, Italy  
**Poewe W**, University of Innsbruck, Austria  
**Post RM**, National Institute of Mental Health, USA  
**Rabinowitz T**, University of Vermont, VT, USA  
**Schneider J**, Thomas Jefferson University, PA, USA  
**Smith MA**, Case Western Reserve University, USA  
**Stojanovic MP**, Massachusetts Gen. Hospital, USA  
**Tanabe H**, Ehime Uni. School of Medicine, Japan  
**Taupin P**, Natl Neuroscience Institute, Singapore  
**Yuki N**, Niigata National Hospital, Japan

**Disclaimer:** Whilst every effort is made by the Publisher and Editorial Board to ensure that no inaccurate or misleading data, opinions or statements appear in this journal, they wish to make it clear that the data and opinions appearing herein are the responsibility of the contributor concerned. Accordingly, the Publisher, Editorial Board and their respective employees, officers and agents accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinions or statements.

**Copyright:** Conditions of sale: *Expert Review of Neurotherapeutics* may be circulated only to those members of staff who are employed at the site at which the subscription is taken out. Readers are reminded that, under internationally agreed copyright legislation, photocopying of copyright materials is prohibited other than on a limited basis for personal use. Thus making copies of any article published in *Expert Review of Neurotherapeutics* is a breach of the law and can be prosecuted.

### Issue themes:

January/July Schizophrenia; Mood disorders  
February/August Stroke; Anxiety disorders  
March/September Migraine and headache; Demyelinating diseases  
April/October CNS neoplasms; Attention-deficit/hyperactivity disorder  
May/November Alzheimer's disease; Pain  
June/December Parkinson's disease; Epilepsy

**Indexing:** Medline/Index Medicus, EMBASE/  
Excerpta Medica, and Chemical Abstracts

[www.expert-reviews.com](http://www.expert-reviews.com)

part of the 

Argentum Pharm. v. Research Corp. Techs., IPR2016-00204  
RCT EX. 2119 - 3/15

“...highly authoritative coverage of the rapidly changing neurological landscape...”

*Expert Review of Neurotherapeutics* provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer’s and Parkinson’s.

**Coverage includes:**

- Leading Reviews on current and emerging topics relating to neurotherapeutics, subject to rigorous peer review
- Cutting-edge Editorials discussing contentious issues
- Drug Profiles of individual therapies discussing the place of the drug in current treatment practices and written with an independent perspective
- Comprehensive Clinical Trial Reports of recently completed or ongoing clinical studies
- Key Paper Evaluations reviewing significant, recently published articles carefully selected and assessed by specialists in neurotherapeutics.

*Expert Review of Neurotherapeutics* provides analysis and commentary on the emerging opportunities, new strategies and the performance of new therapeutic and diagnostic modalities. Members of the International Advisory Panel identify the most important and topical review themes and the corresponding experts most appropriate to provide their opinion and perspective. All articles are subject to rigorous peer-review, and the finished articles make an essential contribution to decision-making in the development and delivery of effective therapy in neurology and neuropsychiatry.

**Subscription Options**

**Institutional subscriptions**

*Expert Review of Neurotherapeutics* is available in print, electronic or print and electronic formats, and pricing will depend on your organization type (academic, corporate, hospital, etc). Please contact [info@expert-reviews.com](mailto:info@expert-reviews.com) for more details.

Global e-access licenses are available on request and attract considerable discounts from standard site license fees. For further details on global access licenses, please contact Simon Boisseau: [s.boisseau@expert-reviews.com](mailto:s.boisseau@expert-reviews.com)

**Consortia pricing**

Expert Reviews welcomes discussion with all consortia, and offers flexible packages and discounted prices. If you have specific questions or would like a quote please contact [info@expert-reviews.com](mailto:info@expert-reviews.com) for more details.

**Personal subscriptions**

Personal subscriptions are currently available to all Expert Reviews journals. Payment must be made from a personal credit card registered to a home address. Print subscriptions will only be sent to a personal address. Please contact [info@expert-reviews.com](mailto:info@expert-reviews.com) for our personal order form.

**Print Subscription Rates**

Journal (12 issues)	€ Euros	US\$
Academic & Hospital	1145.00	1760.00
Corporate, Government & NGO Centers	2500.00	3830.00

Subscribers in North America must pay in US\$. Europe and ROW must pay in € Euros. For subscriptions in territories covered by Technomics or iGroup, please refer to the contact details above for further details.

**Ordering Information**

Please contact your local sales representative to place an order:

**Worldwide**

Expert Reviews Ltd  
 Unitec House, 2 Albert Place, London N3 1QB, UK  
 T: +44 (0)20 8371 6080  
 F: +44 (0)20 8371 6099  
 E: [subscriptions@expert-reviews.com](mailto:subscriptions@expert-reviews.com)

**North America**

E: [sales.us@expert-reviews.com](mailto:sales.us@expert-reviews.com)

**Latin America and the Caribbean**

Systems Link International  
 T: +1 305 826 6191  
 E: [informacion@systemsint.info](mailto:informacion@systemsint.info)

**China**

Charlesworth China  
 T: +86 106 779 1601  
 E: [sales@charlesworth.com.cn](mailto:sales@charlesworth.com.cn)

**Japan**

Technomics Inc.  
 T: +81 (03) 3666 2952  
 E: [sales@technomics.co.jp](mailto:sales@technomics.co.jp)

**Asia (excluding Japan & China)**

iGroup Asia Pacific  
 T: +852 2572 7228  
 E: [info.kh@igroup.com](mailto:info.kh@igroup.com)

**Reprints**

Article reprints are available through our reprint service. Please contact Joanne Walker: [j.walker@expert-reviews.com](mailto:j.walker@expert-reviews.com)



Argentum Pharm. v. Research Corp. Techs., IPR2016-00204  
 RCT EX. 2119 - 4/15

Expert Reviews titles endorse the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, issued by the International Committee for Medical Journal Editors, and Code of Conduct for Editors of Biomedical Journals, produced by the Committee on Publication Ethics. This information is also available at [www.expert-reviews.com](http://www.expert-reviews.com)

#### Manuscript submission & processing

Expert Reviews titles publish a range of article types, including solicited and unsolicited reviews, perspectives and original research articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to external review. Initial screening of articles by internal editorial staff will assess the topicality and importance of the subject, the clarity of presentation, and relevance to the audience of the journal in question. If you are interested in submitting an article, or have any queries regarding article submission, please contact the Managing Commissioning Editor for the journal (contact information can be found on our website at [www.expert-reviews.com](http://www.expert-reviews.com)). For new article proposals, the Managing Commissioning Editor will require a brief article outline and working title in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Advisory Panel, solicits articles directly for publication.

#### External peer review

Through a rigorous peer review process, Expert Reviews titles aim to ensure that reviews are unbiased, scientifically accurate and clinically relevant. All articles are peer reviewed by three or more members of the International Advisory Board or other specialists selected on the basis of experience and expertise. Review is performed on a double-blind basis – the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal (see Conflict of Interest Policy below). Peer reviewers complete a referee report form, provide general comments to the editor and both general and specific comments to the author(s).

Where an author believes that an editor has made an error in declining a paper, they may submit an appeal. The appeal letter should clearly state the reasons why the author(s) considers the decision to be incorrect and provide detailed, specific responses to any comments relating to the rejection of the review. Further advice from members of the journal's Editorial Advisory Panel external experts will be sought regarding eligibility for re-review.

#### Revision

Most manuscripts require some degree of revision prior to acceptance. Authors should provide two copies of the revised manuscript – one of which should be highlighted to show where changes have been made. Detailed responses to reviewers' comments, in a covering letter/email, are also required. Review manuscripts may be accepted at this point or may be subject to further peer review. The final decision on acceptability for publication lies with the journal editor.

#### Post-acceptance

Accepted review manuscripts are edited by the in-house Expert Reviews editorial team. Authors will receive proofs of their article for approval and sign off and will be asked to sign a transfer of copyright agreement, except in circumstances where the author is ineligible to do so (e.g. government employees in some countries).

#### Author disclosure & conflict of interest policy

Authors must state explicitly whether potential conflicts do or do not exist (e.g. personal or financial relationships that could influence their actions) and any such potential conflict of interest (including sources of funding) should be summarized in a separate section of the published review. Authors must disclose whether they have received writing assistance and identify the sources of funding for such assistance. Authors declaring no conflict of interest are required to publish a statement to that effect within the article.

Authors must certify that all affiliations with or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in their manuscript have been disclosed. Please note that examples of financial involvement include: employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending and royalties. This is list is not exclusive of other forms of financial involvement. Details of relevant conflicts of interests (or the lack of) must be declared in the 'Disclosure' section of the manuscript for all listed authors.

External peer reviewers must disclose any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. Should any such conflict of interest be declared, the journal editor will judge whether the reviewer's comments should be recognized or will interpret the reviewer's comments in the context of any such declaration.

#### Ethical conduct of research

For studies involving data relating to human or animal experimental investigations, appropriate institutional review board approval is required and should be described within the article. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations involving human subjects, authors should explain how informed consent was obtained from the participants involved.

#### Patients' rights to privacy

Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be included unless the information is essential for scientific purposes and the patient (or parent or legal guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. When informed consent has been obtained it should be indicated in the manuscript.

In attempting to maintain patient anonymity, identifying details should be omitted where they are not essential. However, patient data should never be amended or falsified. Informed consent should be obtained whenever there is any doubt that anonymity can be assured.

#### Use of personal communications & unpublished data

Where an individual is identified within a review as a source of information in a personal communication or as a source for unpublished data, authors should include a signed statement of permission from the individual(s) concerned and specify the date of communication.

#### Clinical trial registration

Expert Reviews titles prefer to publish clinical trials that have been included in a clinical trials registry that is accessible to the public at no charge, is electronically searchable, is open to prospective registrants and is managed by a not-for-profit organization, such as [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (sponsored by the United States National Library of Medicine). Whilst referees will take registration status into account, all well designed and presented trials and corresponding data will be considered for publication.

#### Errata/corrigenda

Mistakes by either editor or author should be identified wherever possible and an erratum or corrigendum published at the earliest opportunity. We will attempt to contact the author of the original article to confirm any error, and publish an appropriate erratum or corrigendum at the earliest opportunity.

#### Permissions for reproduced or adapted material

Authors must acknowledge the origin of all text, figures, tables or other information that has been adapted or reproduced from other publications. Authors must provide a copy of the original source documents and should submit permission from the authors of the original work and the original publishers for unlimited use in all markets and media (that includes both electronic and print use in any language).

#### Duplicate publication/submission & plagiarism

All manuscripts submitted to Expert Reviews titles are considered for publication on the understanding that they have not been published previously elsewhere or are under consideration for publication elsewhere. The journal may, however, consider republication of a paper previously published in a language other than English, subject to prominent disclosure of the original source and with any necessary permission. Authors will be asked to certify that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, except as described in an attachment, and copies of closely related manuscripts are provided. The use of published or unpublished ideas, words or other intellectual property derived from other sources without attribution or permission, and representation of such as those of the author(s) is regarded as scientific misconduct and will be addressed as such.

#### Misconduct

If misconduct by authors or reviewers is suspected, either pre- or post-publication, action will be taken. An explanation will be sought from the party or parties considered to be involved. If the response is unsatisfactory, then an appropriate authority will be asked to investigate fully. Expert Reviews will make all reasonable attempts to obtain a resolution in any such eventuality and correct the record or archive as necessary.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.